This proposal is a continuation of an ongoing epidemiologic study of HIV-1 infection amount intravenous drug users. This study proposes to: 1) Estimate the incidence of antibodies to HIV-1 among a cohort of IVDUs; 2) Conduct a case-control study of incident seropositive IVDU cases and seronegative controls; 3) Estimate mortality rates for seroprevalent, seroincident and seronegative IVDUs; and 4) Conduct survival analysis to estimate relative survival from time of seroconversion to death or the common closing of he study and to determine prognostic factors that related to survival and death. The cohort of 700 IVDUs that is being followed in the initial grant will form the primary study sample for this continuation. In order to address Aims 1, 3 and 4, this cohort of 700 IVDUs who have been tested for sero-status while in drug treatment programs will be followed at 6 month intervals for 2.5 years. When combined with data from the original grant, 3.5 to 4.5 years of follow-up data will be available for analysis. In addition, IVDUs from an AIDS risk reduction program will be pooled with the cohort of 700 to accrue sufficient cases to carry out the case-control study-AIM 2. There are four phases to this project. In phase 1, the original cohort of IVDUs who tested negative at baseline for HIV-1 AB will be rescreened at 6 month intervals for seroconversion to determine the proportion who seroconvert (become HIV AB+). In phase 2, individuals who seroconvert (seroincident cases) will be pooled with seroincident cases from the risk reduction program to accrue cases for the case-control study. Four controls (seronegative subjects) per case will be randomly selected from the seronegative pool. Phase 3 will use follow-up data to estimate morality rates among subgroups in the original cohort. Phase 4 will perform survival analysis, estimate relative survival and determine prognostic factors for survival.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
2R01DA004433-03A1
Application #
3210066
Study Section
Biobehavioral/Clinical Subcommittee (DAAR)
Project Start
1987-07-01
Project End
1992-06-30
Budget Start
1989-07-01
Budget End
1990-06-30
Support Year
3
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of Miami School of Medicine
Department
Type
Schools of Medicine
DUNS #
City
Miami
State
FL
Country
United States
Zip Code
33101
Shah, S M; Shapshak, P; Rivers, J E et al. (1996) Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: a preliminary laboratory report. J Acquir Immune Defic Syndr Hum Retrovirol 11:301-6
McCoy, C B; Shapshak, P; Metsch, L R et al. (1995) HIV-1 prevention: interdisciplinary studies on the efficacy of bleach and development of prevention protocols. Arch Immunol Ther Exp (Warsz) 43:1-9
Chitwood, D D; Griffin, D K; Comerford, M et al. (1995) Risk factors for HIV-1 seroconversion among injection drug users: a case-control study. Am J Public Health 85:1538-42
McElrath, K; Chitwood, D D; Griffin, D K et al. (1994) The consistency of self-reported HIV risk behavior among injection drug users. Am J Public Health 84:1965-70
Shapshak, P; McCoy, C B; Shah, S M et al. (1994) Preliminary laboratory studies of inactivation of HIV-1 in needles and syringes containing infected blood using undiluted household bleach. J Acquir Immune Defic Syndr 7:754-9
McCoy, C B; Rivers, J E; McCoy, H V et al. (1994) Compliance to bleach disinfection protocols among injecting drug users in Miami. J Acquir Immune Defic Syndr 7:773-6
Shapshak, P; McCoy, C B; Rivers, J E et al. (1993) Inactivation of human immunodeficiency virus-1 at short time intervals using undiluted bleach. J Acquir Immune Defic Syndr 6:218-9
Chitwood, D D; Page, J B; Comerford, M et al. (1991) The donation and sale of blood by intravenous drug users. Am J Public Health 81:631-3
Chitwood, D D; McCoy, C B; Inciardi, J A et al. (1990) HIV seropositivity of needles from shooting galleries in south Florida. Am J Public Health 80:150-2